PDE4D Variant Risk Stratification Guided by TMPRSS2-ERG Status
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current post-surgical risk stratification methods for prostate cancer lack the precision needed for personalized treatment decisions, leading to unnecessary side effects from aggressive therapies.
Innovation Solution
Determine the TMPRSS2-ERG fusion status and select appropriate phosphodiesterase 4D (PDE4D) variants for gene expression profiling, combining this molecular information with clinical variables to calculate a post-surgical prognostic risk score, thereby improving treatment decision-making.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If aggressive secondary treatments are administered to all post-surgical prostate cancer patients, then disease progression is prevented, but side effects increase substantially
Solution Approach 1:
The patent applies local quality by differentiating treatment approaches based on individual patient characteristics. Specifically, it uses molecular biomarkers (TMPRSS2-ERG fusion status and PDE4D variant expression) to identify which patients truly need aggressive therapy versus those who can receive conservative management, thereby concentrating intensive treatment only where medically necessary rather than applying it uniformly to all patients
Solution Approach 2:
The patent segments the post-surgical prostate cancer patient population into distinct risk stratification groups based on molecular profiling. By dividing patients into high-risk and low-risk categories using specific biomarker thresholds, the system enables tailored treatment recommendations that match therapeutic intensity to actual disease risk, preventing unnecessary aggressive treatment in low-risk patients while ensuring adequate treatment for high-risk patients
2Measurement precision
If post-surgical risk stratification uses only clinical variables, then treatment decisions are simple, but precision for personalized treatment is insufficient
Solution Approach 1:
The patent merges multiple types of diagnostic information into a unified risk stratification system. It combines traditional clinical variables (pathological Gleason score, TNM classification, surgical margin status) with molecular biomarker data (TMPRSS2-ERG fusion status and PDE4D variant expression levels) to create a comprehensive risk assessment that leverages both clinical expertise and molecular precision
Solution Approach 2:
The patent introduces molecular biomarkers as intermediary elements that bridge clinical observation and treatment decision-making. The TMPRSS2-ERG fusion status and PDE4D variant expression serve as intermediate molecular indicators that translate complex tumor biology into actionable risk stratification categories, enabling more precise treatment recommendations without requiring direct interpretation of complex molecular data by clinicians
Data Source
AI summary
The invention relates to a method of post-surgical risk stratification of a prostate cancer subject, comprising determining a transmembrane protease, serine 2-ETS-related gene (TMPRSS2-ERG) fusion status in a biological sample obtained from the subject, determining a gene expression profile for each of one or more phosphodiesterase 4D variants in a biological sample obtained from the subject, determining an expression based risk score for the subject based on the gene expression profile for a selected phosphodiesterase 4D variant, and determining a post-surgical prognostic risk score for the subject based on the expression based risk score and post-surgical clinical variables of the subject, wherein the selected phosphodiesterase 4D variant is selected depending on the TM-PRSS2-ERG fusion status. This may allow for an improved stratification of the subject in a post-surgical setting that may result in better post-surgical, secondary treatment decisions.